Gavsmate Tablet 50/500 mg

Adult dose

The initial dose of this medication is 50/500 mg once daily, taking one tablet, and can be gradually increased to 50/1000 mg twice daily, taking one tablet at each dose. A dosage of vildagliptin exceeding 100 mg per day is not recommended. This medication is generally administered with meals or immediately after eating to reduce gastrointestinal side effects associated with metformin. Combination treatment of vildagliptin and metformin.

This medication can cause severe lactic acidosis or hypoglycemia, and should not be administered to patients at risk for these symptoms. It is especially contraindicated for patients with moderate to severe renal impairment, severe heart failure, or acute cardiac conditions and sepsis. Patients undergoing examinations using radiocontrast iodinated agents should discontinue use of this medication 48 hours prior to the exam and only resume after confirming normal renal function. This medication is not administered to patients with hypersensitivity to it, type 1 diabetes patients, or patients with diabetic ketoacidosis. Caution should be exercised when administering to patients with severe infections, trauma, pre- and post-surgery, malnutrition, liver dysfunction, pulmonary dysfunction, or excessive alcohol consumption. It is safest not to administer this medication to pregnant or breastfeeding women. Due to the risk of hypoglycemia, caution is advised in cases of irregular meals, intense exercise, or concurrent use of other blood sugar-lowering agents. During treatment, regular monitoring of liver and kidney function should be conducted, and any abnormalities should be reported to a physician immediately. If symptoms of acute pancreatitis occur, the medication should be stopped immediately and medical attention should be sought. Alcohol intake may increase the risk of side effects of this medication, so it is advisable to avoid drinking during treatment. Patients should be vigilant for symptoms of hypoglycemia and take appropriate action immediately if they occur. Elderly patients may have decreased renal function and require dose adjustment and regular monitoring of renal function. In the event of overdose, prompt medical attention should be sought, and hem dialysis may be necessary. Store this medication in a tightly closed container, out of reach of children, and do not transfer to another container. Particularly, this medication is not recommended for patients suspected of or diagnosed with mitochondrial diseases, and if any adverse symptoms occur, it should be discontinued immediately, and a diagnostic evaluation should be performed.

Serious side effects

• Hives, severe swelling (edema), angioedema, chest tightness, difficulty breathing, cold sweat, pallor, severe allergic reactions
• Severe rash, blisters, peeling skin with high fever, pain in the mucous membranes of the mouth/eyes, severe skin reactions
• Yellowing of the skin or eyes (jaundice), extreme fatigue, liver abnormalities (jaundice)
• Sudden and very severe headache, thunderclap headache, seizures, confusion, visual disturbances, paralysis, severe

Mild side effects

• Tremors
• headache
• dizziness
• fatigue
• nausea
• gastroesophageal reflux
• diarrhea
• bloating
• chills
• decreased blood sugar

This medication is sensitive to air and moisture, so it should be stored in a tightly sealed container. It is also advisable to keep it in a cool place with a temperature below 30 degrees.

Appearance

Bright yellow oval film-coated tablets

Package unit

60 tablets (10 tablets/PTP packaging × 6)